Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1264
- Registration Number
- NCT03268005
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Vinnytsia, Ukraine
Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas
- Conditions
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03262116
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT03215498
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
- Conditions
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 597
- Registration Number
- NCT03211858
- Locations
- 🇺🇸
Investigational Site Number 8400033, Chattanooga, Tennessee, United States
🇺🇸Investigational Site Number 8400009, Dallas, Texas, United States
🇺🇸Investigational Site Number 8400024, Henderson, Nevada, United States
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT03202875
- Locations
- 🇩🇪
Investigational Site 276001, Neuss, Germany
A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 47
- Registration Number
- NCT02938572
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT02933853
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT02910518
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 532
- Registration Number
- NCT02906917
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 472
- Registration Number
- NCT02825251
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, St Helens, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.